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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to a 
combination of Lactobacillus rhamnosus CNCM I-1720 and Lactobacillus 
helveticus CNCM I-1722 and defence against pathogenic gastro-intestinal 
microorganisms (ID 939, further assessment) pursuant to Article 13(1) of 
Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was 
asked to provide a scientific opinion on a health claim related to a combination of Lactobacillus rhamnosus 
CNCM I-1720 and Lactobacillus helveticus CNCM I-1722 and defence against pathogenic gastro-intestinal 
microorganisms. The food constituent that is the subject of the health claim, a combination of Lactobacillus 
rhamnosus CNCM I-1720 and Lactobacillus helveticus CNCM I-1722, is sufficiently characterised. The claimed 
effect, defence against pathogenic gastro-intestinal microorganisms, is a beneficial physiological effect. The 
proposed target population is the general population. No human intervention studies were provided from which 
conclusions could be drawn for the scientific substantiation of the claim. On the basis of the data provided, the 
Panel concludes that a cause and effect relationship has not been established between the consumption of a 
combination of Lactobacillus rhamnosus CNCM I-1720 and Lactobacillus helveticus CNCM I-1722 and defence 
against pathogenic gastro-intestinal microorganisms. 
© European Food Safety Authority, 2012 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. The Commission has agreed with EU Member States that a certain 
number of Article 13 health claims would be eligible for further assessment by EFSA in order to be 
able to take a final decision on whether or not to include these claims in the list of permitted health 
claims. This opinion addresses the scientific substantiation of a health claim in relation to a 
combination of Lactobacillus rhamnosus CNCM I-1720 and Lactobacillus helveticus CNCM I-1722 
and defence against pathogenic gastro-intestinal microorganisms. The scientific substantiation is based 
on the information provided by the competent Authority of the United Kingdom for further assessment 
of this claim.  
The food constituent that is the subject of the health claim is a combination of Lactobacillus 
rhamnosus CNCM I-1720 and Lactobacillus helveticus CNCM I-1722. The Panel considers that the 
combination of Lactobacillus rhamnosus CNCM I-1720 and Lactobacillus helveticus CNCM I-1722 is 
sufficiently characterised.  
The claimed effects, which are proposed for further assessment, are “maintenance of the defence 
against pathogenic gastro-intestinal microorganisms” and “decreasing potentially pathogenic intestinal 
microorganisms”. The proposed target population is the general population. The Panel considers that 
defence against pathogenic gastro-intestinal microorganisms is a beneficial physiological effect. 
Five human intervention studies submitted investigated the effect of the combination of Lactobacillus 
rhamnosus CNCM I-1720 and Lactobacillus helveticus CNCM I-1722 on antibiotic-associated 
diarrhoea. In three of these studies, the evidence provided did not allow establishing the infectious 
nature of the diarrhoeal episodes. The Panel considers that no conclusions can be drawn from these 
studies for the scientific substantiation of a claim related to defence against pathogenic gastro-
intestinal microorganisms. In one study, no information was provided about the baseline 
characteristics of the two study groups, about the type and duration of the antibiotic treatment in the 
two study groups even though development of antibiotic-associated diarrhoea was reported to be 
influenced by the type of antibiotic used, and about the statistical tests used in the data analyses. In 
another study, it was unclear whether the study was randomised, and no information was provided on 
the baseline characteristics of the two study groups, and about the statistical tests used in the data 
analyses. The Panel considers that no conclusions can be drawn from these studies for the scientific 
substantiation of the claim. 
Two open-label trials investigated the effect of the combination of Lactobacillus rhamnosus CNCM I-
1720 and Lactobacillus helveticus CNCM I-1722 as co-adjuvant to antibiotics and proton pump 
inhibitor therapy for Helicobacter pylori eradication. The Panel notes that no evidence was provided 
that results obtained in patients with Helicobacter pylori infection under antibiotics with respect to 
treatment of the disease can be extrapolated to healthy subjects with respect to the development of 
Helicobacter pylori infection. The Panel considers that no conclusions can be drawn from these 
studies for the scientific substantiation of a claim on defence against pathogenic gastro-intestinal 
microorganisms targeted to the general population (i.e. subjects without infections). 
Two studies addressed the use of the combination of Lactobacillus rhamnosus CNCM I-1720 and 
Lactobacillus helveticus CNCM I-1722 for the treatment of acute and chronic diarrhoea of various 
origins, including gastro-intestinal infections, in hospitalised children. The Panel notes that the status 
of the gastro-intestinal tract in subjects with diarrhoea due to a gastro-intestinal infection may not be 
comparable to the status of the gastro-intestinal tract in subjects without gastro-intestinal infection. 
The Panel considers that no conclusions can be drawn from these studies for the scientific 
substantiation of the claim. 
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The Panel notes that no human intervention studies were provided from which conclusions could be 
drawn for the scientific substantiation of the claim. The Panel also notes that the animal and in vitro 
studies which were provided, cannot predict the occurrence of an effect of a combination of 
Lactobacillus rhamnosus CNCM I-1720 and Lactobacillus helveticus CNCM I-1722 on defence 
against pathogenic gastro-intestinal microorganisms in humans. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of a combination of Lactobacillus rhamnosus 
CNCM I-1720 and Lactobacillus helveticus CNCM I-1722 and defence against pathogenic gastro-
intestinal microorganisms. 
A combination of L. rhamnosus CNCM I-1720 and L. helveticus CNCM I-1722 and  
defence against pathogenic gastro-intestinal microorganisms (further assessment)  
 
4 EFSA Journal 2012;10(6):2720 
TABLE OF CONTENTS 
Abstract .................................................................................................................................................... 1 
Summary .................................................................................................................................................. 2 
Table of contents ...................................................................................................................................... 4 
Background as provided by the European Commission ........................................................................... 5 
Terms of reference as provided by the European Commission ................................................................ 5 
EFSA Disclaimer ...................................................................................................................................... 5 
Introduction .............................................................................................................................................. 6 
Assessment ............................................................................................................................................... 6 
1. Characterisation of the food/constituent (ID 939) ............................................................................ 6 
2. Relevance of the claimed effect to human health (ID 939) .............................................................. 7 
3. Scientific substantiation of the claimed effect (ID 939) ................................................................... 7 
Conclusions .............................................................................................................................................. 9 
Documentation provided to EFSA ........................................................................................................... 9 
References ................................................................................................................................................ 9 
Appendices ............................................................................................................................................. 12 
Glossary and Abbreviations ................................................................................................................... 18 
 
 
A combination of L. rhamnosus CNCM I-1720 and L. helveticus CNCM I-1722 and  
defence against pathogenic gastro-intestinal microorganisms (further assessment)  
 
5 EFSA Journal 2012;10(6):2720 
BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
See Appendix A 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
See Appendix A 
EFSA DISCLAIMER 
See Appendix B 
A combination of L. rhamnosus CNCM I-1720 and L. helveticus CNCM I-1722 and  
defence against pathogenic gastro-intestinal microorganisms (further assessment)  
 
6 EFSA Journal 2012;10(6):2720 
INTRODUCTION 
The Commission has agreed with EU Member States that a certain number of Article 13 health claims 
would be eligible for further assessment by EFSA in order to be able to take a final decision on 
whether or not to include these claims in the list of permitted health claims. These claims include 
already assessed claims related to microorganisms which the Panel considered to be not sufficiently 
characterised and claims for which the NDA Panel concluded that there was insufficient evidence to 
establish a cause and effect relationship between the consumption of the food and the claimed effect. 
Following an opinion of the NDA Panel on a health claim pursuant to Article 13 of Regulation (EC) 
No 1924/2006
4
 in which the Panel concluded that a combination of Lactobacillus rhamnosus CNCM 
I-1720 and Lactobacillus helveticus CNCM I-1722, which is the subject of the health claim, is not 
sufficiently characterised (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2009), 
EFSA received additional information from the competent Authority of the United Kingdom for 
further assessment of this claim. The information provided in the framework of further assessment for 
the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent (ID 939) 
The food constituent that is the subject of the health claims is a combination of Lactobacillus 
rhamnosus CNCM I-1720 (hereafter L. rhamnosus CNCM I-1720) and Lactobacillus helveticus 
CNCM I-1722 (hereafter L. helveticus CNCM I-1722). 
The strain L. rhamnosus CNCM I-1720 is also known as L. rhamnosus R0011. A culture collection 
number from the Collection Nationale de Cultures de Microorganismes (CNCM), I-1720, was 
provided. The CNCM is a restricted-access non-public collection, which has the status of an 
International Depositary Authority under the Budapest Treaty. Data on the identification and 
characterisation of L. rhamnosus CNCM I-1720 at species and strain level using both phenotypic (cell 
morphology, colony morphology, carbohydrate fermentation pattern and enzymatic activity profile) 
and genotypic (DNA-DNA hybridisation, 16S rRNA gene sequence analysis, 16S/23S intergenic 
spacer region sequence analysis, RAPD and PFGE) methods were provided in the application and 
accompanying references (Provencher et al., 2003; Roy and Ward, 2004; Yeung et al., 2002) . 
The strain L. helveticus CNCM I-1722 is also known as L. helveticus R0052. A culture collection 
number from the CNCM, I-1722, was provided. Data on the identification and characterisation of 
L. helveticus CNCM I-1722 at species and strain level using both phenotypic (cell morphology, colony 
morphology, carbohydrate fermentation pattern, enzymatic activity profile, antimicrobials resistance 
pattern and PAGE) and genotypic (DNA-DNA hybridisation, 16S rRNA gene sequence analysis, 
16S/23S intergenic spacer region sequence analysis, species-specific PCR, AFLP, MLST, RAPD and 
PFGE) methods were provided in the application and accompanying references (Naser et al., 2006; 
Yeung et al., 2002). 
The formulation which is the subject of the claim is a combination of L. rhamnosus CNCM I-1720 and 
L. helveticus CNCM I-1722 in a 95:5 ratio. 
The Panel considers that the food constituent, a combination of L. rhamnosus CNCM I-1720 and 
L. helveticus CNCM I-1722, which is the subject of the health claim, is sufficiently characterised. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
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2. Relevance of the claimed effect to human health (ID 939) 
The claimed effects which are proposed for further assessment are “maintenance of the defence 
against pathogenic gastro-intestinal (GI) microorganisms” and “decreasing potentially pathogenic 
intestinal microorganisms”. The proposed target population is the general population. 
The presence of pathogenic microorganisms in the GI tract (e.g. viruses and bacteria) may lead to the 
development of GI infections. Defence against GI pathogenic microorganisms may protect against the 
development of GI infections. 
The Panel considers that defence against pathogenic gastro-intestinal microorganisms is a beneficial 
physiological effect. 
3. Scientific substantiation of the claimed effect (ID 939) 
Of the references provided in relation to the claim, nine were human studies (five studies were on 
antibiotic-associated diarrhoea, two related to Helicobacter pylori (hereafter H. pylori) eradication 
therapy, and two on the treatment of diarrhoea), eight were animal studies, and six were in vitro 
studies. Five papers were published in Ukrainian and one in Czech, and their full English translations 
were given. 
All the studies were carried out with the combination of microorganisms that is the subject of the 
health claim, consisting of L. rhamnosus CNCM I-1720 and L. helveticus CNCM I-1722 in a 95:5 
ratio. 
Studies on antibiotic-associated diarrhoea (AAD) 
One study in adults and four studies in children which investigated the effect of the combination of 
L. rhamnosus CNCM I-1720 and L. helveticus CNCM I-1722 on AAD were provided.  
Two studies were conducted in Korean hospitalised adult patients and in Ukrainian children with 
cystic fibrosis, respectively, under antibiotic treatment for respiratory tract infections (Aryayev and 
Kononenko, 2009; Song et al., 2010). The Panel notes that the infectious nature of the diarrhoeal 
episodes was not clearly established by the diagnostic criteria used, that causes of diarrhoea other than 
GI infections were not systematically excluded, that microbiological analyses were not performed, and 
that antibiotic treatment may induce diarrhoea by mechanisms unrelated to GI infections. The Panel 
considers that no conclusions can be drawn from these studies for the scientific substantiation of a 
claim related to defence against pathogenic gastro-intestinal microorganisms. 
In a randomised, open-label study, Marushko and Shef (2007) evaluated the effect of the combination 
of L. rhamnosus CNCM I-1720 and L. helveticus CNCM I-1722 added to antibiotic therapy vs. 
antibiotic therapy alone (control) in a group of 34 hospitalised children with pneumonia or bronchitis 
aged from 10 months to 3 years. The presence and duration of diarrhoea, abdominal pain, abdominal 
bloating and vomiting were measured, and microbiological analyses of stools before and after 
treatment were performed. The Panel notes that the methodology used for the microbiological analyses 
was not well described, that the bacterial groups analysed were not sufficiently characterised as 
pathogens, and that the evidence provided, therefore, did not establish the infectious aetiology of the 
episodes of diarrhoea. The Panel considers that no conclusions can be drawn from this study for the 
scientific substantiation of a claim related to defence against pathogenic gastro-intestinal 
microorganisms. 
Maydannik et al. (2010), in a multicentre, randomised, open-label study, assessed the effect of the 
combination of L. rhamnosus CNCM I-1720 and L. helveticus CNCM I-1722 together with antibiotic 
therapy vs. antibiotic therapy alone (control) on the incidence and duration of diarrhoea, and on the 
presence of C. difficile toxins A and B in 244 children with infections of the respiratory, urinary or 
digestive tracts, and who received antibiotic therapy for not less than seven days. The Panel notes that 
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no information was provided about the baseline characteristics of the two study groups (e.g. age and 
carrier status for С. difficile toxins), that precise information on type and duration of the antibiotic 
treatment in the two study groups was not provided even though development of AAD was reported to 
be influenced by the type of antibiotic used, and that the statistical tests used in the data analyses were 
not described. The Panel considers that no conclusions can be drawn from this study for the scientific 
substantiation of the claim. 
In an open-label study, Gnaytenco et al. (2009) compared the incidence of AAD related to standard 
triple H. pylori eradication therapy (control; omeprazole, amoxicillin and clarithromycin for seven 
days) with the same therapeutic regimen taken together with the combination of L. rhamnosus CNCM 
I-1720 and L. helveticus CNCM I-1722 in 45 subjects. The incidence of diarrhoea was measured and 
the assessment for C. difficile toxins A and B was performed at the beginning and at the end of the 
intervention. The Panel notes that it is unclear whether the study was randomised, that no information 
was provided on the baseline characteristics of the two study groups (e.g. clinical features, age and 
carrier status for С. difficile toxins), and that the statistical tests used in the data analyses were not 
described. The Panel considers that no conclusions can be drawn from this study for the scientific 
substantiation of the claim. 
Studies on H. pylori eradication  
Two open-label trials conducted in subjects with H. pylori infection undergoing treatment with 
antibiotics and proton pump inhibitor therapy for H. pylori eradication assessed the effect of the 
combination of L. rhamnosus CNCM I-1720 and L. helveticus CNCM I-1722 as co-adjuvant therapy 
for H. pylori eradication (Vdovychenkon et al., 2008; Ziemniak, 2006). The Panel notes that no 
evidence was provided that results obtained in patients with H. pylori infection under antibiotics with 
respect to treatment of the disease can be extrapolated to healthy subjects with respect to the 
development of H. pylori infection. The Panel considers that no conclusions can be drawn from these 
studies for the scientific substantiation of a claim on defence against pathogenic gastro-intestinal 
microorganisms targeted to the general population (i.e. subjects without infections). 
Treatment of diarrhoea 
Two studies addressed the use of the combination of L. rhamnosus CNCM I-1720 and L. helveticus 
CNCM I-1722 for the treatment of acute and chronic diarrhoea of various origins, including GI 
infections, in hospitalised children (Tlaskal et al., 1995; 2005). The Panel notes that the status of the 
GI tract in subjects with diarrhoea due to a GI infection may not be comparable to the status of the GI 
tract in subjects without GI infection. The Panel considers that no conclusions can be drawn from 
these studies for the scientific substantiation of the claim. 
Animal and in vitro studies 
The animal studies provided evaluated the effect of the combination of L. rhamnosus CNCM I-1720 
and L. helveticus CNCM I-1722 on the treatment of experimental Citrobacter rodentrium infection in 
adult mice (Johnson-Henry et al., 2005) and neonatal mice (Gareau et al., 2010), on bacterial 
translocation from the intestine to the lymph nodes and on the intestinal barrier function in rats 
experiencing chronic psychological stress (Zareie et al., 2006), on mucin expression in a rat model 
(Dykstra et al., 2011), on colonic macromolecular permeability and corticosterone level in an animal 
model of stress induced by neonatal maternal separation (Gareau et al., 2007), on the rate of H. pylori 
eradication  in Mongolian gerbils (Brzozowski et al., 2006), on H. pylori colonisation in mice 
(Johnson-Henry et al., 2004), and on GI functions and immune markers (e.g. gastric emptying, 
intestinal permeability and gastric CD3+ cell counts) after chronic H. pylori infection in mice (Verdu 
et al., 2008).  
The in vitro studies submitted investigated the effects of a combination of L. rhamnosus CNCM 
I-1720 and L. helveticus CNCM I-1722 on the interaction of Camplylobacter jejuni with a cell line or 
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invasion of T48 epithelial cell line (Alemka et al., 2010; Wine et al., 2009), on cytokine secretion by a 
human intestinal epithelial cell line (Wallace et al., 2003), on epithelial injury (paracellular 
permeability) following exposure to Escherichia coli O157:H7 (Sherman et al., 2005), on adhesion of 
Escherichia coli O157:H7 to epithelial cells (Johnson-Henry et al., 2007), and on the immune effects 
of Escherichia coli O157:H7 infection in epithelial cells (Jandu et al., 2009).  
The Panel notes that no human intervention studies were provided from which conclusions could be 
drawn for the scientific substantiation of the claim. The Panel also notes that animal and in vitro 
studies cannot predict the occurrence of an effect of a combination of L. rhamnosus CNCM I-1720 
and L. helveticus CNCM I-1722 on defence against pathogenic gastro-intestinal microorganisms in 
humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of a combination of L. rhamnosus CNCM I-1720 and L. helveticus CNCM I-1722 and 
defence against pathogenic gastro-intestinal microorganisms. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, a combination of Lactobacillus rhamnosus CNCM I-1720 and 
Lactobacillus helveticus CNCM I-1722, which is the subject of the health claim, is sufficiently 
characterised. 
 The claimed effects proposed for further assessment are “maintenance of the defence against 
pathogenic gastro-intestinal microorganisms” and “decreasing potentially pathogenic 
intestinal microorganisms”. The proposed target population is the general population. Defence 
against pathogenic gastro-intestinal microorganisms is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of a 
combination of Lactobacillus rhamnosus CNCM I-1720 and Lactobacillus helveticus CNCM 
I-1722 and defence against pathogenic gastro-intestinal microorganisms. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 for further assessment (No: 
EFSA-Q-2012-00131). The scientific substantiation is based on the information provided by the 
competent Authority of the United Kingdom for further assessment of this claim (available at: 
http://www.efsa.europa.eu/en/topics/topic/article13.htm). 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
5
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
6
  
Foods are commonly involved in many different functions
7
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to a 
single food is scientifically pertinent.  
It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
                                                     
5  OJ L12, 18/01/2007 
6  The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
7  The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific data, 
and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of the 
application for authorisation of health claims consistent criteria for the potential sources of scientific 
data. Such sources may not be available for all health claims. Nevertheless it will be relevant and 
important that EFSA comments on the availability and quality of such data in order to allow the 
regulator to judge and make a risk management decision about the acceptability of health claims 
included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not enough 
to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. Moreover, 
the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially affect identified 
functions in the body in a way which is relevant to health. Although an appreciation of the beneficial 
effect in relation to the nutritional status of the European population may be of interest, the presence or 
absence of the actual need for a nutrient or other substance with nutritional or physiological effect for 
that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic or 
cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of the 
body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which specifies 
this by using the word "flexibility". 
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The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore be 
specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings should 
be avoided. To this end, wordings like "strengthens your natural defences" or "contain antioxidants" 
should be considered as well as "may" or "might" as opposed to words like "contributes", "aids" or 
"helps".  
In addition, for functions affected by a large number of dietary factors it should be considered whether 
wordings such as "indispensable", "necessary", "essential" and "important" reflects the strength of the 
scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally accepted 
scientific evidence by taking into account the totality of the available scientific data, and by 
weighing the evidence. In this context EFSA is invited to comment on the nature and quality 
of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the extent 
to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
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 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1.  Health claims related to a combination of Lactobacillus rhamnosus CNCM I-1720 
and Lactobacillus helveticus CNCM I-1722 including conditions of use, as proposed in the framework 
of further assessment. 
ID Food or Food constituent Health Relationship Proposed wording 
939 A combination of 2 bacterial 
strains: Lactobacillus 
rhamnosus CNCM I-1720 and 
Lactobacillus helveticus 
CNCM I-1722. 
Maintenance of the defence 
against pathogenic GI 
microorganisms 
Moreover, decreasing 
potentially pathogenic 
intestinal microorganisms 
might be beneficial to 
human health 
Helps to maintain gut health 
by improving defence against 
gastro-intestinal pathogens 
 
Conditions of use 
For adults, the consumption of 8*10
9
 CFU of the food constituent per day to be effective for 
the claimed effect. 
The target population is general population (adults and children). 
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GLOSSARY AND ABBREVIATIONS 
AAD  Antibiotic-associated diarrhoea 
AFLP Amplified fragment length polymorphism 
CFU Colony forming units 
CNCM Collection Nationale de Cultures de Microorganismes 
DNA Deoxyribonucleic acid 
GI Gastro-intestinal 
MLST Multilocus sequence typing  
PAGE Polyacrylamide gel electrophoresis 
PCR Polymerase chain reaction 
PFGE Pulsed field gel electrophoresis 
RAPD Random amplification of polymorphic DNA 
rRNA Ribosomal ribonucleic acid 
